Yokoi T, Kosaka Y, Chida M, Chiba K, Nakamura H, Ishizaki T, Kinoshita M, Sato K, Gonzalez F J, Kamataki T
Division of Drug Metabolism, Faculty of Pharmaceutical Sciences, Hokkaido University, Japan.
Pharmacogenetics. 1996 Oct;6(5):395-401. doi: 10.1097/00008571-199610000-00003.
The CYP2D6 gene of a Japanese sparteine poor metabolizer (PM, proband) showing a urinary sparteine metabolic ratio of 31.6 was analysed, and a heterozygous CYP2D6(D), a deletional type, was found by restriction fragment length polymorphism analysis with Xba I enzyme. The PM did not have any other previously described mutations in the CYP2D6 gene causing the loss of catalytic activity of the CYP2D6 enzyme. Thus, a possible new allele(s) responsible for the PM phenotype was analysed. The results indicated that the PM possessed a new 9-base insertion in exon 9, designated CYP2D6(J9). The CYP2D6(J9) and CYP2D6(D) alleles were clarified to be inherited from the mother [2D6(W)/2D6(J9)] and the father [2D6(W)/2D6(D)], respectively. The 9-base insertion caused a large increase in the apparent K(m) value for bufuralol 1'-hydroxylation as examined by expression of the enzyme protein in yeast. Four of 300 Japanese carried a heterozygous CYP2D6(J9) allele (0.7%, 4/600 chromosomes) as determined by a polymerase chain reaction analysis.
对一名尿中司巴丁代谢率为31.6的日本司巴丁慢代谢者(PM,先证者)的CYP2D6基因进行了分析,通过用Xba I酶进行限制性片段长度多态性分析,发现了一个杂合的CYP2D6(D),即缺失型。该PM在CYP2D6基因中没有任何先前描述的导致CYP2D6酶催化活性丧失的突变。因此,分析了可能导致该PM表型的新等位基因。结果表明,该PM在外显子9中有一个新的9碱基插入,命名为CYP2D6(J9)。CYP2D6(J9)和CYP2D6(D)等位基因分别被明确为从母亲[2D6(W)/2D6(J9)]和父亲[2D6(W)/2D6(D)]遗传而来。通过在酵母中表达酶蛋白检测发现,9碱基插入导致布福洛尔1'-羟基化的表观K(m)值大幅增加。通过聚合酶链反应分析确定,300名日本人中有4人携带杂合的CYP2D6(J9)等位基因(0.7%,4/600条染色体)。